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Background and PurposeaaPercutaneous transluminal angioplasty (PTA) is being increas-
ingly used in the treatment of symptomatic middle cerebral artery (MCA) stenosis. We evalu-
ated the long-term durability after PTA for symptomatic MCA stenosis. 
MethodsaaWe analyzed consecutive patients included in our stroke database who were treat-
ed with angioplasty alone. The subjects without major periprocedural complications were fol-
lowed up for at least 42 months. Recurrent ischemic symptoms were defined as newly devel-
oped episodes of transient ischemic attack or ischemic stroke in the territory of the treated vessel. 
Stroke was defined as ischemic stroke in any vessel.   
ResultsaaPTA was technically successful in 37 of the 40 included patients. Thirty-two of the 
37 patients were followed up at regular intervals of 1 to 6 months in the outpatient clinic of our 
institution for at least 42 months. Restenosis occurred in 3 of the 32 patients (9.4%) within 2 
years of PTA, and no restenosis was identified thereafter. Two of the three patients with re-
stenosis had asymptomatic complications such as dissection and vasospasm during the inter-
vention. The ischemic area was in the treated vessel in 1 of the 32 patients and in other vessels 
in 3 of the 32 patients (9.4%). 
ConclusionsaaSuccessful PTA can result in a low rate of recurrent ischemic symptoms, and 
restenosis during a long-term follow-up appears to be more frequent in the early period. 
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Introduction 
 
Intracranial atherosclerosis is a major cause of ischemic stroke 
(IS) in Asian populations. Previous studies found annual inci-
dences of stroke recurrence in patients with symptomatic mid-
dle cerebral artery (MCA) stenosis of 8-15%.
1-5 Medical treat-
ment has been widely and empircally used, but there is still a 
high rate of failures that result in recurrent transient ischemic 
attack (TIA), stroke, and death in symptomatic patients.
4 Con-
sequently, there is ongoing controversy on the optimal thera-
peutic strategies for these patients. Nowadays endovascular 
therapy has emerged as an alternative potential therapeutic op-
tion for patients with symptomatic MCA stenosis. With recent 
imrovements in microcatheter technology, percutaneous trans-
minal angioplasty (PTA) is now being increasingly used in 
the treatment of symptomatic MCA stenosis. There are sev-
eral reports of fair results of PTA in selected patients with in-
tracranial arterial disease,
3,6,7 but there are few reports on the 
long-term durability of PTA for MCA stenosis.
8 Restenosis 
after endovascular treatment has emerged as a significant com-
plication, with a reported rate as high as 32%.
3 Therefore, the 
present study evaluated the long-term durability of PTA for 
symptomatic MCA stenosis.   
 
Methods 
 
Subjects and data collection 
We analyzed consecutive patients included in our stroke da-
tabase who were treated with angioplasty alone. Between Feb-
ruary 1996 and December 2004, 56 patients underwent 57 PTA  
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procedures for the treatment of symptomatic MCA stenosis 
at our institution. Exclusion criteria comprised acute interven-
tion performed within 3 days of symptom onset (n=2), under-
going MCA angioplasty for the treatment of acute cardio-
genic embolic occlusion (n=11) or vasospasm after subara-
chnoid hemorrhage (n=2), and atherosclerotic stenosis in the 
M2 segment of the MCA (n=1).
9 All patients and their family 
members provided informed consents before the procedure. 
All patients had severe MCA stenosis (>50% luminal narrow-
ing) with ischemic symptoms despite medical treatment. Brief-
ly, the stenosis percentage was quantified as the diameter of 
maximal narrowing (D narrow) relative to the diameter of the 
normal (D normal) symptomatic MCA just distal or proximal 
to the stenosis: {1–(D narrow/D normal)}×100%.
10 The nor-
mal portion of the MCA was defined as where the MCA walls 
appeared parallel on angiography.   
 
Interventional technique and postprocedural 
management 
PTA was performed by two experienced radiologists. The de-
tailed method for PTA has been reported previously.
9 A 6-F 
guiding catheter was inserted into the cervical portion of the 
internal carotid artery over an exchange wire. The first 30 pa-
tients were treated with Stealth angioplasty balloons (Target 
Therapeutics, Fremont, CA), and the last 10 patients were 
treated with coronary balloons (HayatePro, Terumo, Tokyo, 
Japan). The balloon was inflated slowly with a screw-type 
pressure inflation device at 2-4 atm for 30-60 seconds either 
once or twice. Follow-up angiography was performed using 
a guiding catheter after the procedure, and the degree of re-
sidual stenosis was recorded. We defined technical success 
as a residual stenosis of less than 50% on follow-up angio-
grams without any serious complications. After the procedure, 
heparin was infused intravenously for 24 hours, and antiplate-
let medication (a daily dose of 325 mg of aspirin plus 250 
mg ticlopidine or 75 mg clopidogrel) was maintained contin-
uously during the follow-up period.   
 
Imaging follow-up 
Imaging follow-up was performed with CT angiograms at 6 
months, 12 months, and yearly or biannually thereafter. Regu-
lar transcranial Doppler (TCD) follow-up was performed on 
32 patients for first 6 months. After these, 19 patients under-
went regular TCD follow-ups. A single-channel 2-MHz Dop-
pler device was used for TCD examinations. M1 MCA was 
defined as an insonation depth of 45-65 mm.
11,12 All record-
ings were performed by an experienced sonographer who was 
not involved in the other aspects of the study. Patients regu-
larly underwent TCD examinations on day 1 and at months 
1 and 6 after PTA. We evaluated several parameters, includ-
ing the mean flow velocity (MFV) and peak systolic velocity 
(PSV), in order to assess flow velocity changes after PTA.   
 
Radiological and clinical outcomes 
Major complications were defined as symptomatic and severe 
neurological deficits related to procedures, and minor peripro-
cedural complications were defined as asymptomatic or tran-
sient neurological deficits. Restenosis was defined as an in-
crease in the MFV of >30 cm/sec between two consecutive 
TCD examinations or as >50% stenosis measured on follow-
up CT angiograms. If velocity changes remained below this 
threshold, the stenosis was considered to be stable. When a de-
crease of >30 cm/s was observed, we considered MCA steno-
sis to have regressed. This threshold value of 30 cm/s for son-
ographic progression and regression was based on previous-
ly described criteria.
13 Recurrent ischemic symptoms were de-
fined as newly developed episodes of TIA or ischemic stroke 
in the territory of the treated vessel. Stroke was defined as is-
chemic stroke in any vessel.   
 
Statistical analysis 
Except where stated otherwise, data are presented as median 
values for continuous variables and as percentages for categor-
ical variables. We compared baseline demographics and clini-
cal risk factors using the chi-square test for categorical varia-
bles and Student’s t-test for continuous risk factors between 
the TIA and ischemic stroke groups. We also used the Wilcox-
on signed-rank test to compare baseline and follow-up TCD 
values. The Kaplan-Meyer method was used to estimate event-
free survival rates. The data were analyzed using SPSS ver-
sion 14.0.   
 
Results 
 
Clinical outcomes  
PTA was technically successful in 37 of the 40 patients, with 
major complications (subarachnoid hemorrhage and cerebral 
infarction) in 2 cases and 1 case of technical failure. Other pe-
riprocedural complications were asymptomatic or no neuro-
logical sequelae (2 TIAs, 3 intimal dissections, and 1 vaso-
spasm). The rate of minor periprocedural complications was 
16.2% (6 of 37 patients). Thirty-two of the 37 patients were 
followed up at regular intervals of 1 to 6 months in the outpa-
tient clinic of our institution for at least 42 months. There-
fore, the 32 subjects included in this study underwent suc-
cessful PTA without any major periprocedural complications 
and were followed up for at least 42 months. They compris-
ed 18 men and 14 women with a mean age of 56.5 years. Pre-
senting symptoms were TIA in 21 patients (65.6%) and is-
chemic stroke in 11 patients (34.4%). The degree of stenosis  
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before the procedure ranged from 50% to 95% (median, 
75.5%), whereas the degree of residual stenosis after the pro-
cedure ranged from 9% to 48% (median, 21%). The general 
characteristics of the subjects (including risk factors and treat-
ment) did not differ significantly between the two groups 
(Table 1). During the median follow-up period of 56 months 
(range, 42 to 115 months), restenosis occurred in 3 of the 32 
patients (9.4%) within 2 years of PTA, and no restenosis was 
identified thereafter (Fig. 1). Two of the 3 patients with reste-
nosis had asymptomatic complications such as dissection and 
vasospasm during the intervention (Table 2). The ischemic 
area was in the treated vessel in 1 of the 32 patients and in 
other vessels in 3 of the 32 patients (9.4%)(Fig. 2). 
 
Transcranial Doppler findings 
TCD examinations showed a preprocedural MFV of 165.9± 
47.6 cm/s (mean±SD) and a preprocedural PSV of 208.7± 
61.2 cm/s (n=32), which declined to 146.2±53.9 and 186.4± 
68.7 cm/s, respectively, immediately after the procedure (p< 
0.05). In patients with serial TCD evaluations, the MFV and 
PSV gradually declined during 6 months of follow-up (n=19, 
p<0.05)(Table 3).  
 
Discussion 
 
In this study, the rates of restenosis and recurrent ischemic 
Table 1. General characteristics of the subjects 
Characteristic 
TIA 
(n=21) 
IS 
(n=11) 
Total 
(n=32) 
Age* (years)  52.5  64.2  56.5 
Prestenosis* (%)  73.7  75.7  74.4 
Poststenosis* (%)  24.2  23.6  24.0 
Follow-up* (months)  53  56  56 
Risk factors† (%, n)       
Hypertension 61.9  (13)  63.6 (7)  62.5 (20) 
Diabetes 09.5  (2)0  18.2 (2)  12.5 (4)0 
Lipidemia 23.8  (5)0  36.4 (4)  28.1 (9)0 
Smoking 23.8  (5)0  36.4 (4)  28.1 (9)0 
History of stroke  28.6 (6)0  18.2 (2)  25.1 (8)0 
Treatment† (%, n)       
Single 33.3  (7)0  27.3 (3)  31.3 (10) 
Combination 66.7  (14)  72.7 (8)  68.7 (22) 
*Student’s t-test for continuous risk factors was applied, †The chi-
square test for categorical variables was applied. 
TIA: transient ischemic attack, IS: ischemic stroke. 
   
Table 2. Characteristics of subjects with restenosis 
  1  2  3 
Site of stenosis   Right, M1, mid  Left, M1, mid  Right, M1, mid 
Presentation   TIA  TIA  IS 
Prestenosis (%)  56  60  57 
Poststenosis (%)  45 12 14 
Detection   19  14  18 
(months)      
Follow-up   79  54  54 
(months)      
Follow-up  
examination 
Angiogram 
 
CT angiogram 
 
CT angiogram 
 
Procedure event 
 
Vasospasm 
 
None 
 
Asymptomatic
dissection 
Associated  
events 
None 
 
None 
 
None 
 
TIA: transient ischemic attack, IS: ischemic stroke. 
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Fig. 1. Arterial patency after angioplasty excluding patients with
significant postprocedural complications. The restenosis rate was
9.37% (3 of the 32 patients) within 2 years of PTA, and no reste-
nosis was identified thereafter. PTA: percutaneous transminal an-
gioplasty.   
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Fig. 2. Ischemic events occurring after successful PTA. The ische-
mic area was in the treated vessel in 1 of the 32 patients and in 
other vessels in 3 of the 32 patients. PTA: percutaneous transmi-
nal angioplasty.    
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events were lower for successful PTA for MCA stenosis, with 
there being no patients with restenosis 2 years after PTA. Com-
pared with previous data on the risk of medically treated MCA 
stenosis, the long-term durability and outcomes of successful 
PTA appear favorable.
1,4 Recurrent ischemic events in the 
distribution of the treated vessel occurred in 3.1% of the pa-
tients within a median follow-up period of 56 months. In ad-
dition, major procedural complications after PTA that caused 
residual deficits or death were uncommon.
9 Subjects with ma-
jor procedural complications after PTA were excluded from 
the present study in order to assess the durability of success-
ful PTA in patients with symptomatic MCA stenosis. Our 
results indicate that successful PTA can maintain the patency 
of the treated artery for up to 115 months. Wojak et al. attribu-
ted a decrease in the rate of ischemic symptoms after angio-
plasty to multiple factors such as an increase in vessel lumen, 
which increases blood flow, and remodeling of the endo-
thelial surface to a smoother surface, which theoretically is 
less thrombogenic.
14 In our study, the TCD data showed that 
the MFV at the stenotic artery did not decrease from normal 
values until 12 months after PTA. This result indicates that the 
remodeling of the vessel surface and the widening of vessel 
lumen can take several months after PTA, and also suggests 
that restenosis is more likely to develop in the early period 
after PTA. However, Fiorella et al. reported that the prepro-
cedural velocity of 127.7 cm/s declined to 54.0 cm/s immedi-
ately after the procedure.
15 This difference might have been 
due to technical differences. Although our results differ from 
previous reports, TCD appears to be a favorable modality for 
follow-up after PTA.
11,13-15 Future studies should investigate 
this difference. In addition, long-term durability of PTA could 
be favorable despite the possibility of complications or re-
stenosis in the early period. The reported restenosis rate after 
angioplasty has ranged from 15% to 50%.
7,8,14,16,17 Mazighi et 
al. recently reported that restenosis after treatment was asso-
ciated with a vessel size of <2.5 mm or interventions that 
were performed in the setting of an acute stroke.
8 Two of our 
three restenosis subjects were associated with asymptomatic 
procedural problems such as vasospasm and dissection. How-
ever, factors associated with restenosis were not found in this 
study, and restenosis was not related to clinical recurrence. 
Therefore, we consider restenosis to be a slowly progressing 
event after PTA. Recurrent stroke occurred in four patients 
during the follow-up period. However, recurrent stroke in the 
territory of the treated artery did not occur with the excep-
tion of one occurrence of TIA, which demonstrates that PTA 
reduces the rate of recurrent events in the territory of the 
treated artery.   
The results of this study are subject to at least two limita-
tions: 1) the use of a small sample with single-center results 
and 2) the use of imperfect follow-up imaging studies for 
evaluating restenosis, since conventional angiography (which 
is the reference standard) was performed in only a few patients. 
Although TCD was performed on some patients during the 
follow-up, it has several disadvantages in the diagnosis of 
MCA stenosis.   
From the results of this study, it is concluded that success-
ful PTA in patients with symptomatic MCA stenosis is associ-
ated with a low long-term rate of recurrent ischemic symp-
toms and that restenosis after the procedure is more frequent 
in the early period. However, restenosis does not appear to be 
associated with ischemic symptoms. Further studies are need-
ed to evaluate the long-term efficacy and safety of PTA. 
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